Purple Biotech Presents Phase 1 Cancer Data at ESMO TAT
Ticker: PPBT · Form: 6-K · Filed: Feb 27, 2024 · CIK: 1614744
Sentiment: bullish
Topics: biotech, clinical-trial, cancer, presentation
TL;DR
**Purple Biotech just presented early-stage data for its cancer drug NT219 in combination with Cetuximab at a major medical conference!**
AI Summary
Purple Biotech Ltd. announced on February 27, 2024, that it issued a press release detailing the presentation of Phase 1 data for its investigational drug NT219. The data, focusing on Head & Neck Cancer in combination with Cetuximab, was presented at the ESMO TAT Congress 2024, marking a significant step in its clinical development.
Why It Matters
Presenting early-stage (Phase 1) clinical trial data for a novel drug combination at a prominent medical congress like ESMO TAT indicates progress in drug development and could attract further investment or partnerships for potential future treatments for Head & Neck Cancer.
Risk Assessment
Risk Level: medium — While presenting data is a positive step, Phase 1 trials are very early in drug development, and the success of the drug in later, larger clinical trials is not guaranteed.
Key Numbers
- February 27, 2024 — Press Release Date (Date of announcement regarding data presentation)
- Phase 1 — Clinical Trial Stage (Stage of clinical trial data presented)
Key Players & Entities
- Purple Biotech Ltd. (company) — registrant
- NT219 (drug) — investigational drug
- Cetuximab (drug) — combination drug
- ESMO TAT Congress 2024 (event) — presentation venue
- Head & Neck Cancer (disease) — target indication
- February 27, 2024 (date) — press release date
FAQ
What is the name of the company filing this 6-K report?
The company filing this 6-K report is Purple Biotech Ltd.
What did Purple Biotech Ltd. announce on February 27, 2024?
On February 27, 2024, Purple Biotech Ltd. announced it issued a press release titled 'Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024'.
Which specific drugs were involved in the data presentation mentioned in the press release?
The data presentation involved NT219 in combination with Cetuximab.
What stage of clinical trial was the data presented for?
The data presented was from a Phase 1 clinical trial.
At which congress was the data presented?
The data was presented at the ESMO TAT Congress 2024.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-02-27 07:10:20
Filing Documents
- ea0200773-6k_purple.htm (6-K) — 13KB
- ea0200773ex99-1_purple.htm (EX-99.1) — 19KB
- 0001213900-24-017134.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. February 27, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2